Moxidectin: an oral treatment for human onchocerciasis

Milton, P; Hamley, JID; Walker, M; Basáñez, MG

Abstract

Moxidectin is a milbemycin endectocide recently approved for the treatment of human onchocerciasis. Onchocerciasis, earmarked for elimination of transmission, is a filarial infection endemic in Africa, Yemen, and the Amazonian focus straddling Venezuela and Brazil. Concerns over whether the predominant treatment strategy (yearly mass drug administration (MDA) of ivermectin) is sufficient to achieve elimination in all endemic foci have refocussed attention upon alternative treatments. Moxidectin’s stronger and longer microfilarial suppression compared to ivermectin in both phase II and III clinical trials indicates its potential as a novel powerful drug for onchocerciasis elimination.

Citation

Milton, P., Hamley, J., Walker, M., & Basáñez, M. (2020). Moxidectin: an oral treatment for human onchocerciasis. Expert Review of Anti-infective Therapy, 1-15. https://doi.org/10.1080/14787210.2020.1792772

• Journal Article Type: Article
• Acceptance Date: Jul 3, 2020
• Publication Date: Jul 26, 2020
• Deposit Date: Aug 14, 2020
• Publicly Available Date: Aug 14, 2020
• Journal: Expert Review of Anti-infective Therapy
• Print ISSN: 1478-7210
• Electronic ISSN: 1744-8336
• Publisher: Taylor and Francis
• Peer Reviewed: Peer Reviewed
• Pages: 1-15
• DOI: https://doi.org/10.1080/14787210.2020.1792772
• Public URL: https://rvc-repository.worktribe.com/output/1376625
• Publisher URL: https://doi.org/10.1080/14787210.2020.1792772